Fig. 3.

SRI(4) response at week 52 by analysis populations in TULIP-1 and TULIP-2

Data were from the pooled exposure–response analysis set. Response rates and treatment difference for SRI(4) were calculated using the AME approach based on logistic regression models by treating quartile/median groups along with placebo group as one covariate, and stratification factors by SLEDAI-2K score at screening (<10 points vs ≥10 points), day 1 oral glucocorticoid dose (<10 mg/day vs ≥10 mg/day prednisone or equivalent) and type I IFNGS at screening (high vs low), whenever applicable. Tertiles (µg/ml) were defined as: G1 <31.2, G2 ≥31.2 to <43.8 and G3 ≥43.8; quartiles (µg/ml) were defined as: Q1 <27.6, Q2 ≥27.6 to <39.2, Q3 ≥39.2 to <49.8 and Q4 ≥49.8. AME: average marginal effect; G: tertile; IFNGS: type I IFN gene signature; n: number of patients; N: number of patients in group; Q: quartile; SLEDAI-2K: SLE Disease Activity Index 2000; SRI(4): SLE Responder Index of ≥4.